+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market Size, Share and Trends Analysis Report by Test (Molecular Diagnostics, Immunoassays), End-use (Clinics and Hospitals, Diagnostic Laboratories), and Country 2024-2030

  • PDF Icon

    Report

  • 80 Pages
  • September 2024
  • Region: Asia Pacific
  • Grand View Research
  • ID: 6009824
Description Jump to:
The Asia Pacific point of care TB and drug-resistant TB testing market size is anticipated to reach USD 4.0 billion by 2030 and is projected to grow at a CAGR of 6.6% from 2024 to 2030. The high prevalence of tuberculosis (TB) in the region is primarily driving market’s growth. Countries like India, China, Indonesia, and the Philippines contribute significantly to the global TB burden. For instance, India alone accounted for about 27.0% of the world's TB cases in 2022, according to the World Health Organization (WHO). This high incidence necessitates efficient diagnostic solutions to manage and control TB, including drug-resistant forms.

Recent technological advancements are also fueling market growth. Innovations such as rapid molecular diagnostic tests, including the GeneXpert MTB/RIF assay, significantly improve diagnostic speed and accuracy. These technologies enable fast detection of TB and drug resistance, providing results in hours rather than days or weeks. Such advancements are crucial in high-burden areas where timely diagnosis is essential to prevent the spread of disease and improve patient outcomes. Integrating digital health solutions and automated testing systems further enhances diagnostic capabilities, supporting market expansion.

Government initiatives and regulatory support play a substantial role in driving market growth. Governments across the Asia Pacific are investing in TB control programs and diagnostic infrastructure to combat the high TB burden. For example, India's National Strategic Plan for Tuberculosis Elimination 2017-2025 emphasizes enhancing diagnostic services. Similarly, international organizations such as the Global Fund provide financial and technical assistance to improve diagnostic and treatment capabilities. These efforts and streamlined regulatory processes that facilitate the approval & adoption of new diagnostic technologies are crucial in supporting the market's growth and ensuring effective TB management in the region.

Asia Pacific Point of Care TB And Drug-resistant TB Testing Market Report Highlights

  • Based on test, the immunoassays segment dominated the market with a substantial revenue share of 34.6% in 2023. This prominence can be attributed to the technology's established efficacy, ease of use, and adaptability in diverse settings.
  • Based on end use, the clinics and hospitals segment dominated the market with the largest revenue share of 48.0% in 2023. This prominence is primarily driven by the critical role these healthcare settings play in comprehensive patient management, advancements in diagnostic technologies, and the escalating need for effective TB and drug-resistant TB diagnostics.
  • In July 2023, EMPE Diagnostics launched the mfloDx MDR-TB rapid test kit, a precise, quick, and inexpensive test that provides accurate information on Mycobacterium tuberculosis presence and genotypic resistance. It was approved by the CDSCO and is currently undergoing clinical testing in other nations.
  • Several manufacturers are actively involved in Mergers and acquisitions (M&A) activities in this regional market, showcasing dynamic growth and consolidation

The leading players in the Asia Pacific Point of Care TB and Drug-Resistant TB Testing market include:

  • Cepheid (Danaher Corporation)
  • Molbio Diagnostics
  • Abbott Laboratories
  • BD (Becton, Dickinson and Company)
  • Roche Diagnostics
  • Qiagen
  • Lucira Health
  • BioMérieux
  • Thermo Fisher Scientific
  • Fujifilm (Fujifilm Healthcare)
  • MedMira
  • SD Biosensor
  • Trivitron Healthcare

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Asia Pacific
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test
2.2.2. End Use
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High TB Burden
3.2.1.2. Increased Awareness and Government Initiatives
3.2.1.3. Improving Healthcare Infrastructure
3.2.1.4. Technological Advancements
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Advanced Diagnostic Tests
3.2.2.2. Regulatory and Approval Challenges
3.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Estimates & Trend Analysis
4.1. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Dashboard
4.2. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
4.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market by Test, Revenue
4.4. Molecular Diagnostics
4.4.1. Molecular Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Immunoassays
4.5.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Culture-based Tests
4.6.1. Culture-based Tests market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Serological Tests
4.7.1. Serological Tests market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Estimates & Trend Analysis
5.1. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Dashboard
5.2. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
5.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Clinics and Hospitals
5.4.1. Clinics and Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Diagnostic Laboratories
5.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Regional Estimates & Trend Analysis by Test, and End Use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. Asia Pacific
6.3.1. Japan
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. China
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. India
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Australia
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework/ reimbursement structure
6.3.4.3. Competitive scenario
6.3.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Southeast Asia
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework/ reimbursement structure
6.3.5.3. Competitive scenario
6.3.5.4. Southeast Asia market estimates and forecasts 2018 to 2030 (USD Million)
6.3.6. Rest of APAC
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework/ reimbursement structure
6.3.6.3. Competitive scenario
6.3.6.4. Rest of APAC market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key company market share analysis, 2023
7.2.3. Cepheid (Danaher Corporation)
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Molbio Diagnostics
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Abbott Laboratories
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. BD (Becton, Dickinson and Company)
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Roche Diagnostics
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Qiagen
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Lucira Health
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. BioMérieux
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Thermo Fisher Scientific
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Fujifilm (Fujifilm Healthcare)
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. MedMira
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. SD Biosensor
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Trivitron Healthcare
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
List of Tables
Table 1 List Of Abbreviation
Table 2 Asia Pacific PoC TB and Drug-Resistant TB Testing Market, By Region, 2018 - 2030 (USD Million)
Table 3 Asia Pacific PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 4 Asia Pacific PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 5 Japan PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 6 Japan PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 7 China PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 8 China PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 9 India PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 10 India PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 11 Australia PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 12 Australia PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 13 Southeast Asia PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 14 Southeast Asia PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 15 Rest of APAC PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 16 Rest of APAC PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Asia Pacific
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Market Outlook
Fig. 14 Asia Pacific PoC TB and Drug-Resistant TB Testing Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Asia Pacific PoC TB and Drug-Resistant TB Testing Market Driver Impact
Fig. 18 Asia Pacific PoC TB and Drug-Resistant TB Testing Market Restraint Impact
Fig. 19 Asia Pacific PoC TB and Drug-Resistant TB Testing Market Strategic Initiatives Analysis
Fig. 20 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
Fig. 21 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Outlook And Key Takeaways
Fig. 22 Molecular Diagnostics market estimates and forecast, 2018 - 2030
Fig. 23 Immunoassays market estimates and forecast, 2018 - 2030
Fig. 24 Culture-based Tests market estimates and forecast, 2018 - 2030
Fig. 25 Serological Tests market estimates and forecast, 2018 - 2030
Fig. 26 Others market estimates and forecast, 2018 - 2030
Fig. 27 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
Fig. 28 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Outlook And Key Takeaways
Fig. 29 Clinics and Hospitals market estimates and forecast, 2018 - 2030
Fig. 30 Diagnostic Laboratories market estimates and forecast, 2018 - 2030
Fig. 31 Other market estimates and forecast, 2018 - 2030
Fig. 32 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Japan key country dynamics
Fig. 34 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 China key country dynamics
Fig. 36 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 India key country dynamics
Fig. 38 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Australia key country dynamics
Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Southeast Asia key country dynamics
Fig. 42 Southeast Asia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Rest of APAC key country dynamics
Fig. 44 Rest of APAC market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Market share of key market players- PoC TB and Drug-Resistant TB Testing market

Companies Mentioned

The leading players in the Asia Pacific Point of Care TB and Drug-Resistant TB Testing market include:
  • Cepheid (Danaher Corporation)
  • Molbio Diagnostics
  • Abbott Laboratories
  • BD (Becton, Dickinson and Company)
  • Roche Diagnostics
  • Qiagen
  • Lucira Health
  • BioMérieux
  • Thermo Fisher Scientific
  • Fujifilm (Fujifilm Healthcare)
  • MedMira
  • SD Biosensor
  • Trivitron Healthcare

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages80
PublishedSeptember 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 4 Billion
Compound Annual Growth Rate6.6%
Regions CoveredAsia Pacific
No. of Companies Mentioned13

Related Topics

Related Reports

Lateral Flow Immunoassay (LFIA)-based Rapid Test Global Market Report 2024 - Product Image

Lateral Flow Immunoassay (LFIA)-based Rapid Test Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Global Point of Care & Rapid Diagnostics Market by Platform (Dipstick, Immunoassay, Microfluidics), Sample (Blood, Urine), Purchase, End-User - Forecast 2024-2030 - Product Image

Global Point of Care & Rapid Diagnostics Market by Platform (Dipstick, Immunoassay, Microfluidics), Sample (Blood, Urine), Purchase, End-User - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Point Of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By End-use (Clinics, Home, Hospitals), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Point Of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By End-use (Clinics, Home, Hospitals), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 295 Pages
  • Global
From
Europe Point of Care TB and Drug-Resistant TB Testing Market Size, Share and Trends Analysis Report by Test (Molecular Diagnostics, Immunoassays), End-use (Clinics & Hospitals), and Country 2024-2030 - Product Image

Europe Point of Care TB and Drug-Resistant TB Testing Market Size, Share and Trends Analysis Report by Test (Molecular Diagnostics, Immunoassays), End-use (Clinics & Hospitals), and Country 2024-2030

  • Report
  • 80 Pages
  • Europe
From
Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 178 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.